Recently we showed evidence that mutation of Tyr-335 to Ala (Y335A) in the human dopamine transporter (hDAT) alters the conformational equilibrium of the transport cycle. Here, by substituting, one at a time, 16 different bulky or charged intracellular residues, we identify three residues, Lys-264, Asp-345, and Asp-436, the mutation of which to alanine produces a phenotype similar to that of Y335A. Like Y335A, the mutants (K264A, D345A, and D436A) were characterized by low uptake capacity that was potentiated by Zn 2؉ . Moreover, the mutants displayed lower affinity for cocaine and other inhibitors, suggesting a role for these residues in maintaining the structural integrity of the inhibitor binding crevice. The conformational state of K264A, Y335A, and D345A was investigated by assessing the accessibility to MTSET ([2-(trimethylammonium)ethyl]methanethiosulfonate) of a cysteine engineered into position 159 (I159C) in transmembrane segment 3 of the MTSET-insensitive "E2C" background (C90A/C306A). Unlike its effect at the corresponding position in the homologous norepinephrine transporter (NET I155C), MTSET did not inhibit uptake mediated by E2C I159C. Furthermore, no inhibition was observed upon treatment with MTSET in the presence of dopamine, cocaine, or Zn 2؉ . Without Zn 2؉ , E2C I159C/K264A, E2C I159C/ Y335A, and E2C I159C/D345A were also not inactivated by MTSET. In the presence of Zn 2؉ (10 M), however, MTSET (0.5 mM) caused up to ϳ60% inactivation. As in NET I155C, this inactivation was protected by dopamine and enhanced by cocaine. These data are consistent with a Zn 2؉ -dependent partial reversal of a constitutively altered conformational equilibrium in the mutant transporters. They also suggest that the conformational equilibrium produced by the mutations resembles that of the NET more than that of the DAT. Moreover, the data provide evidence that the cocaine-bound state of both DAT mutants and of the NET is structurally distinct from the cocaine-bound state of the DAT.
The dopamine transporter (DAT) 1 is responsible for the rapid re-uptake of dopamine released upon neuronal stimulation (1) (2) (3) . In this way, the transporter controls the availability of dopamine in the synaptic cleft and thereby plays a key role in regulating the broad spectrum of physiological function mediated by dopamine (1) (2) (3) . The critical physiological role of DAT has been illustrated by targeted disruption of the DAT gene in mice, which resulted in multiple deficits and profoundly altered dopaminergic neurotransmission (4, 5) . Furthermore, the DAT has been the focus of much attention because it represents the principle target for the action of widely abused psychostimulants such as cocaine and amphetamine (3, 6) .
The DAT is a prototypic member of the class of Na ϩ /Cl Ϫ -dependent transporters, along with neurotransmitter transporters, including the norepinephrine (NET), serotonin (SERT), ␥-aminobutyric acid, and glycine transporters (3, 6) . This family of transporters is believed to contain 12 putative transmembrane segments (TMs) connected by alternating extracellular and intracellular loops (ICLs) with an intracellular location of the N and C termini ( Fig. 1) (3, 6) . A high-resolution structure is not yet available for DAT or any related transporter, and our insight into the packing of the 12 helices remains limited (3, 6) . The first series of proximity relationships have only quite recently been described in the tertiary structure of the human DAT (hDAT) (7) (8) (9) . Interestingly, an increasing amount of evidence suggest that the DAT exists in the membrane as an oligomeric structure, but the functional significance of this still needs to be clarified (10 -13) .
Transport of substrate mediated by Na ϩ /Cl Ϫ -dependent transporters is energetically coupled to the transmembrane sodium gradient maintained by the Na ϩ /K ϩ -ATPase (14) . Accordingly, binding of Na ϩ (two ions in case of DAT) together with substrate is assumed to trigger a critical conformational change that leads to transition of the transporter from an "outward" facing conformation in which the substrate binding site is exposed to the extracellular medium to an "inward" facing conformation in which the substrate binding site is exposed to the intracellular environment (14) . This allows for the release of substrate and sodium and potential return of the empty transporter to an outward facing conformation (14) .
A prerequisite for such an alternating access model is the existence of both external and internal "gates," that is protein domains that undergo significant conformational changes dur-ing the transport cycle and are capable of occluding access to the substrate binding site from the extracellular or intracellular environment, respectively. Currently we know rather little about these putative gating domains, although the application of the substituted cysteine accessibility method has identified several conformationally active regions of the transporter (15) (16) (17) (18) (19) . We also know very little about the molecular mechanisms governing the equilibrium between the distinct conformational states in the transport cycle, although this must be tightly regulated for proper transporter function. Interestingly, we have recently identified a tyrosine in the third ICL of hDAT that may play a key role in regulating this conformational equilibrium (20) . This inference was primarily based on the observation that mutation of the tyrosine alters completely the effect of Zn 2ϩ at the previously identified endogenous Zn 2ϩ binding site in the hDAT (Refs. 7 and 8 and Fig. 1 ). In the WT, Zn 2ϩ acts as a potent non-competitive inhibitor of transport via interaction with three residues on the extracellular face of the transporter (Fig. 1) (7) . In marked contrast, in the Tyr-335 mutant (Y335A) this inhibitory Zn 2ϩ switch is converted into a stimulatory Zn 2ϩ switch, i.e. the transporter only displays efficient uptake in the presence of Zn 2ϩ (20) . We inferred that mutation of Tyr-335 produced a constitutive shift in the distribution of conformational states in the transport cycle and that this shift could be reversed in part by Zn 2ϩ . A major alteration of the conformational equilibrium in Y335A was further supported by a substantial decrease of up to 150-fold in the apparent affinity for cocaine and related inhibitors and a parallel increase of up to 20-fold in the apparent affinity for substrates (20) .
We proposed that Tyr-335 is part of a network of intramolecular interactions, possibly in the gating domains themselves, that is important for stabilizing the transporter in a conformational state that maintains the structural integrity of the inhibitor binding site and to which extracellular substrate can bind and initiate transport (20) . If this hypothesis is correct, mutation of other residues might display a similar phenotype as the Y335A mutation, due to their participation in the same network of regulatory intramolecular interactions. In this study, we have sought to test this hypothesis and accordingly to identify additional intracellular residues with a similar phenotype as Y335A. In agreement with our prediction, we identify three residues of 16 mutated charged or bulky residues on the predicted intracellular face of the transporter with such a phenotype. These residues are either in the same loop as Tyr-335, ICL 3, or in the "adjacent" ICL 2 and ICL 4. Furthermore, we establish a structural read-out of the conformational state of the mutant transporters by using the reactivity of a cysteine engineered into position 159 in TM 3. This position was chosen based on recent observations by Rudnick and co-workers (17) in the homologous SERT and NET indicating that the accessibility of the corresponding residue (position 155 in NET and 179 in SERT) to the positively charged sulfhydryl-reactive compound MTSET ([2-(trimethylammonium)-ethyl]-methanethiosulfonate) is dependent on whether the transporter assumes an outward facing conformation or an inward facing conformation. Consistent with our hypothesis, the accessibility data provide direct structural support for an alteration in the conformational equilibria of the mutant transporters that can be reversed in part by Zn 2ϩ
MATERIALS AND METHODS
Site-directed Mutagenesis-We generated a synthetic hDAT (syn-DAT) gene that encodes a protein with an amino acid sequence identical to that of hDAT WT, but the nucleotide sequence was altered to increase the number of unique restriction sites and to optimize codon utilization. The nucleotide sequence of this construct and its generation will be described elsewhere. 2 We have used this synthetic construct in previous work, and its expression and function are identical to DAT encoded by the wild type DAT gene (10, 21) . The E2C background was generated by mutation in the synDAT background of Cys-90 and Cys-306 to alanine. These two endogenous cysteines were previously demonstrated to be accessible to charged sulfhydryl reagents applied extracellularly (15) . This construct was designated "E2C," because the two extracellular cysteines were mutated. The synDAT gene and synDAT E2C gene were subcloned into pcDNA3 (Invitrogen) using the restriction sites for KpnI and XbaI. All mutations were generated by two-step PCR mutagenesis using Pfu polymerase (Promega, Madison, WI) with either synDAT WT or synDAT E2C as templates. The mutant PCR fragments were digested with the appropriate enzymes and cloned into the expression vector, purified by agarose gel electrophoresis and ligated into the vector using the TaKaRa ligation kit (Takara Bio Inc., Shiga, Japan). All mutations were confirmed by restriction enzyme mapping and DNA sequencing using an ABI 310 automated sequencer according to the manufacturer's instructions.
Indexing of Residues-A generic numbering scheme for amino acid residues in the family of Na ϩ /Cl Ϫ -coupled transporters has recently been proposed to facilitate direct comparison of positions between the individual members of the transporter family (22) . According to this scheme the most conserved residue in each transmembrane segment has been given the number 50, and each residue is numbered according to its position relative to this conserved residue. For example, 1.55 indicates a residue in TM1 five residues carboxyl-terminal to the most conserved residue in this TM (Trp1.50). For the DAT, the most conserved residues in each transmembrane domain is as follows: TM1, Trp-84; TM2, Pro-112; TM3, Tyr-156; TM4, Cys-243; TM5, Leu-287; TM6, Gln-317; TM7, Phe-356; TM8, Phe-412; TM9, Gly-468; TM10, Gly-500; TM11, Pro-529; TM12, Gly-561. The generic numbers for residues mutated in this study are (in superscript): Arg-60 1 11.40 , and Tyr-578 12.67 . In E2C we have mutated Cys-90 1.56 and Cys-306 6.39 .
Expression in COS-7 Cells-COS-7 cells were maintained at 37°C in 10% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 0.01 mg/ml gentamicin (all from Invitrogen). WT and mutant transporters were transiently transfected into COS-7 cells by the calcium phosphate precipitation method as previously described (23, 24) .
[ 3 H]Dopamine Uptake Experiments-Uptake assays were performed as modified from Giros et al. (25) using 2,5,6-[ 3 H]dopamine (7-21 Ci/ mmol) (Amersham Biosciences). The uptake assays were carried out 2 days after transfection of transiently transfected COS-7 cells. Twenty hours after transfection, the cells were plated in poly-D-lysine-coated 24-or 12-well dishes (1 or 3 ϫ 10 5 cells/well, respectively) depending on the expression level of the particular mutated transporter to achieve an uptake level of 5-10% of total added [ 3 H]dopamine. Prior to the experiment, the cells were washed once in 500 l of uptake buffer (25 mM HEPES adjusted to pH 7.4 upon addition of 130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgSO 4 , 1 mM L-ascorbic acid, 5 mM D-glucose, and 1 M of the catechol-O-methyltransferase inhibitor Ro 41-0960 (Sigma) at room temperature. Non-labeled compounds (dopamine, norepinephrine, Zn 2ϩ , CFT (2␤-carbomethoxy-3␤-(4-fluorophenyl)tropane), cocaine, or GBR 12,909) were added to the cells at the indicated concentrations. When the cells were co-incubated with 10 M Zn 2ϩ and the indicated non-labeled compound, Zn 2ϩ was added to the uptake media prior to the addition of non-labeled compound. Uptake was initiated by addition of 50 -90 nM [ 3 H]dopamine in a final volume of 500 l of uptake buffer. After 10 min of incubation at 37°C, the cells were washed twice with 500 l of ice-cold uptake buffer, lysed in 300 l of 1% SDS, and left for 1 h at 37°C. All samples were subsequently transferred to 24-well counting plates (PerkinElmer Life Sciences) followed by addition of 600 l of Opti-phase HiSafe 3 scintillation fluid (PerkinElmer Life Sciences). The samples were counted in a Wallac Tri-Lux ␤ scintillation counter (PerkinElmer Life Sciences). Nonspecific uptake was determined in the presence of 1 mM dopamine (RBI, Natick, MA). All determinations were performed in triplicate.
[ 3 H]Norepinephrine Uptake Experiments-Assays were performed as described above for [ 3 H]dopamine uptake experiments, except that the [ 3 H]dopamine was substituted by 40 -80 nM [7, H]norepinephrine (6 -12 Ci/mmol) (Amersham Biosciences).
Surface Biotinylation-Biotinylation of cell surface proteins was per-formed essentially as described (26) by reaction with the membrane impermeant amine-specific biotinylating reagent sulfo-NHS-SS-biotin (Pierce). Transfected COS-7 cells were seeded in poly-D-lysine-coated 100-mm cell culture dishes (Corning) at 2.5 ϫ 10 6 cells/dish and grown for 24 h before the experiment. The cells were washed with ice-cold phosphate-buffered saline/Ca-Mg (pH 7.3), before treatment with sulfo-NHS-SS-biotin (1.5 mg/ml) at 4°C for 40 min in phosphate-buffered saline/Ca-Mg followed by three washes with TBS (0.05 M Tris, pH 7.4, 0.3 M NaCl) and three washes with phosphate-buffered saline/Ca-Mg. The cells were solubilized in 1 ml of solubilization buffer (25 mM Tris, pH 7.5, with 1.0% Triton X-100, 150 mM NaCl, 1 mM EDTA, 5 mM N-ethylmaleimide, 200 M phenylmethylsulfonyl fluoride, and a protease inhibitor mixture tablet (Roche Diagnostics)), scraped off and left for 30 min at 4°C with constant shaking. Lysates were centrifuged at 20,000 ϫ g for 30 min at 4°C, and the protein concentration in the supernatants was determined using the BCA assay kit (Pierce). Monomeric avidin beads (175 l) (Pierce) were added to 500 g of total protein from each sample. The volume was adjusted to 1.0 ml with solubilization buffer and the samples were incubated for 1 h at room temperature. The beads were washed four times with 800 l of solubilization buffer, before elution with 50 l of 2ϫ loading buffer (100 mM Tris-HCl, pH 6.8, 20% glycerol, 10% SDS, 0.1 M dithiothreitol, and 0.2% bromphenol blue) for 30 min at 37°C. The eluates (25 l) were resolved by SDS-PAGE (10%) and immunoblotted with the rat monoclonal antibody MAB 369 directed against the NH 2 terminus of the hDAT (Chemicon) diluted 1:1000. Immunoreactive bands were visualized using goat anti-rat horseradish peroxidase-conjugated secondary antibody (1:10,000) and Pico Luminescence (Pierce). Quantification of bands was performed by densitometry measures using Scion Image (Scion, Frederick, MD) using film exposures that were in the linear range.
MTSET Experiments-Two days after transfection, cells seeded in 12-or 24-well plates were washed once with 500 l of uptake buffer (see above). The cells were subsequently incubated with 0.5 mM MTSET ([2-(trimethylammonium)ethyl]methanethiosulfonate) (Toronto Research Chemicals, Toronto, Canada) (unless another concentration is indicated) at 37°C for 10 min. The stock MTSET solution was freshly prepared in H 2 O and immediately diluted 10-fold by application to the transfected cells into a final volume of 500 l of uptake buffer. After incubation, the cells were washed twice in 500 l of uptake buffer before initiation of [ 3 H]dopamine uptake, performed as described above. The effects of substrates and blockers on MTSET reactivity were investigated by the addition of 100 M dopamine or 10 M cocaine immediately prior to the addition of MTSET. Subsequently, the cells were washed twice in 500 l of uptake buffer before initiation of [ 3 H]dopamine uptake assay.
Data Calculations-Uptake data and binding data were analyzed by nonlinear regression analysis using Prism 3.0 from GraphPad Software, San Diego, CA. The IC 50 values used in the estimation of K m for uptake were calculated from means of pIC 50 values and the S.E. interval from the pIC 50 Ϯ S.E. The K I values were calculated from the IC 50 values using the equation K I ϭ IC 50 /(1 ϩ (L/K m )), L ϭ concentration of [ 3 H]dopamine. One-way analysis of variance followed by Newman-Keuls multiple comparison post-hoc test was used for statistical comparisons of the response to MTSET treatment. To achieve an exact measure for the low specific transporter-mediated [ 3 H]dopamine uptake for the E2C I159C/Y335A mutant with no Zn 2ϩ present, an uptake experiment on mock-transfected COS-7 cells was performed in parallel. The nonspecific uptake in these cells was subtracted from the total uptake in E2C I159C/Y335A expressing cells. The nonspecific uptake was less than 20% of total uptake in E2C I159C/Y335A.
RESULTS

Mutation of Selected Intracellular Residues in the hDAT-To
identify residues that upon mutation might display the same phenotype as our previously described Tyr-335 to alanine mutation (Y335A), we selected 16 residues distributed throughout the intracellular domain of the hDAT (Fig. 1 ). First, we selected a series of tyrosines and phenylalanines that were either conserved in all or in many of the mammalian Na ϩ /Cl Ϫ -coupled transporters ( Fig. 2 ): Phe-123 in ICL 1; Tyr-343 in ICL 3; Phe-438 in ICL 4; Tyr-519 in ICL 5; and Tyr-578 in the COOH terminus (for the generic number of these residues according to the numbering scheme proposed by Goldberg et al. see indexing under "Materials and Methods"). Next we selected a series of highly conserved charged residues because we hypothesized that such residues might be involved in important intramolecular interactions critical for maintaining the proper conformational equilibrium of the transport cycle. The selected residues included: Arg-60 and Glu-61 in the NH 2 terminus; Lys-260 and Lys-264 in ICL 2; Arg-344 and Asp-345 in ICL 3; Asp-421, Glu-428, Asp-436, and Glu-437 in ICL 4; and Asp-507 in ICL5. As is apparent from the alignment in Fig. 2 , our selection of residues was representative but was not a comprehensive selection of all the conserved intracellular residues in the DAT with a bulky or charged side chain.
The selected residues were mutated to alanine one at a time and functionally characterized after transient expression in COS-7 cells. As shown in Table I , all the mutants were functional as assessed by measurement of [ 3 H]dopamine uptake. Like 335A, several mutants, including K264A, D345A, D436A, F438A, and D507A, displayed a substantially lowered V max (Ͻ10% of WT). Also similar to Y335A, the K264A, D345A, and D436A mutations displayed lower K m values than the WT (7-9-fold) but this was not the case for F438A and D507A, which had K m values similar to the WT (Table I) . Of the mutants, only one (D421A) had a K m value higher than the WT (8 versus 1.7 M, Table I) .
Effect of Zn 2ϩ on Intracellular Mutants-The effect of Zn 2ϩ on [ 3 H]dopamine uptake mediated by the mutants was subsequently investigated. In the hDAT WT, Zn 2ϩ is a potent noncompetitive inhibitor of [ 3 H]dopamine uptake showing a biphasic inhibition curve with an IC 50 for the high affinity phase of around 1 M and Ͼ1000 M for the low affinity phase (Ref. 7 and Table I , Fig. 3 ). The high affinity inhibition is because of the interaction of Zn 2ϩ with a tridentate Zn 2ϩ binding site involving His-193, His-375, and Glu-396 (Refs. 7 and 8, and Fig. 1 ). In Y335A, the interaction of Zn 2ϩ with this endogenous site does not inhibit uptake but instead causes a remarkable potentiation of uptake (20) . In most of the current mutants, Zn 2ϩ potently inhibited [ 3 H]dopamine uptake with an apparent affinity similar to that of WT (Table I) . In contrast, the three mutants, which displayed the most marked decrease in V max and K m values, were not inhibited but rather potentiated by Zn 2ϩ at micromolar concentrations ( Fig. 3 ). The potentiation is illustrated by the "raw" data ( Fig. 3A ) and by a normalized curve showing the relative change in uptake ( Fig. 3B ). Under the experimental conditions used (i.e. a subsaturating concentration of [ 3 H]dopamine), D345A showed the largest relative increase in uptake, followed very closely by K264A, whereas D436A showed the smallest degree of potentiation ( Fig. 3 ). Of interest, we combined D436A with E437A to test the possibility that the neighboring negatively charged residue, Glu-437, may compensate for the absence of Asp-436 to produce the more modest phenotype of D436A as compared with K264A, Y335A, and D345A. In support of this hypothesis, the decrease in V max and in K m as well as the potentiation by Zn 2ϩ were much more pronounced in the double mutant, despite the fact that E437A alone displayed WT-like properties, including potent inhibition of uptake by Zn 2ϩ (Table I and data not shown).
The mechanism underlying the potentiating effect of Zn 2ϩ shown in Fig. 3 for K264A and D345A was investigated by performing saturation [ 3 H]dopamine uptake experiments in the presence and absence of Zn 2ϩ . These experiments showed that the potentiating effect was because of a substantial increase in V max in response to Zn 2ϩ and not a decrease in K m (Table II) . The K m values were in fact slightly increased in the presence of Zn 2ϩ (Table II) . In K264A, V max increased ϳ14-fold and in D345A V max increased ϳ8-fold (Table II ). In the previously described Y335A mutation, the increase was somewhat larger, ϳ20-fold (Table II and Ref. 20) . However, the uptake mediated by Y335A was substantially lower even in presence of Zn 2ϩ than that of hDAT WT (Table II) , whereas uptake in both K264A and D345A was restored to WT levels (Table II) . All three mutants were nonetheless expressed to a similar degree on the surface of the transfected COS-7 cells as determined by surface biotinylation experiments (Fig. 4A ). According to a densitometry analysis K264A displayed a surface expression of 77 Ϯ 21% and D345A 100 Ϯ 25% of that of the WT (mean Ϯ S.E., n ϭ 4) ( Fig. 4B ). In our previous study Y335A was found to express at 80 Ϯ 2% of the level of the WT (20) .
Effect of Intracellular Mutations on Binding of Transporter Inhibitors-In all mutants, we tested the ability of the cocaine analog CFT (2␤-carbomethoxy-3␤-(4-fluorophenyl)tropane) to inhibit [ 3 H]dopamine uptake. The three mutants, which displayed Zn 2ϩ potentiation (D345A, K264A, and D436A), also had decreased apparent affinity for CFT, with the largest effects for D345A (ϳ6-fold), followed by K264A (ϳ5-fold) and D436A (ϳ3-fold) ( Fig. 5A , Table I ). Of interest, the apparent affinity for CFT in D421A, which also displayed an increased K m for [ 3 H]dopamine, was decreased 10-fold as compared with that of the WT (Table I ). In the remaining mutants the apparent affinity for CFT was similar to that of the WT (Table I) .
In our subsequent studies we focused on K264A and D345A and their comparison to the previously published mutant Y335A (20) . As compared with WT, K264A and D345A had a lower apparent affinity for CFT as well as for cocaine and GBR 12,909. For cocaine, the calculated K I values for K264A and D345A were ϳ1800 and ϳ2,600 nM, respectively, as compared with ϳ370 nM for WT and ϳ26,000 nM for Y335A (Table II) (20) . Thus, compared with Y335A, the effect on cocaine binding was less dramatic although still appreciable in K264A and D345A. In the presence of Zn 2ϩ , the apparent affinities for cocaine increased in all three mutants as well as in WT (Table II) . For GBR 12,909 the effect of mutating Lys-264 and Asp-345 was smaller than for cocaine both in the absence (3-4-fold) and presence of Zn 2ϩ (2-fold or less). Similarly, the apparent affinity of GBR 12,909 for Y335A was only ϳ10-fold lower than WT in the absence of Zn 2ϩ and ϳ5-fold lower in the presence of Zn 2ϩ in agreement with our previous observations (Table II  and (Table IV) . Simi-FIG. 1. Two-dimensional schematic representation of the human dopamine transporter. The residues highlighted on the intracellular side are residues mutated to alanines in the present study (enlarged gray circles with black letters or black circles with white letters). The previously described mutation Y335A is indicated by a white letter in an enlarged gray circle (20) . Position Ile-159, which was mutated to cysteine and alanine is also highlighted (black letter in enlarged white circle). The residues on the extracellular side coordinating Zn 2ϩ binding to the endogenous Zn 2ϩ binding site in hDAT are shown as enlarged gray circles with white letters (7, 8) .
larly, the K m values for both [ 3 H]dopamine and [ 3 H]norepinephrine uptake were lower in all three mutants than in hDAT both in the presence and absence of Zn 2ϩ (2-10-fold) ( (Table IV) .
Assessing the Conformational State of the Mutant Transporters-Previously we proposed that the characteristic phenotype of the Tyr-335 mutation was caused by a constitutive shift in the distribution of conformational states in the transport cycle (20) . To substantiate this hypothesis we wished to establish a structural read-out of the conformational state of the transporter mutants. Rudnick and co-workers (17) in the NET (Ile-179 in SERT) may depend on whether the transporter assumes an outward facing conformation or an inward facing conformation. In NET, in the presumed outward facing conformation, the substituted cysteine (hNET I155C) was found to be accessible to MTSET, resulting in inactivation of the transporter (ϳ90% inactivation with 0.5 mM MTSET) (17) . Dopamine protected against this inactivation, whereas cocaine dramatically enhanced the MTSET inactivation (ϳ100% inactivation with 0.25 mM MTSET) (17) . Because the protection by dopamine was both temperature-dependent and sodium-dependent, it was most likely because of a substratepromoted conversion of the transporter to an inward facing conformation that buries the cysteine in the protein structure rather than the result of a direct steric inhibition of the reaction of the inserted cysteine with MTSET (17) . We hypothesized that a cysteine inserted into the corresponding position (Ile-159) of our mutants could be used as a conformational sensor distinguishing outward from inward facing conformations and thus might enable us to obtain further structural evidence for an altered conformational equilibrium of the mutant transporters.
The I159C mutation was introduced into a background hDAT construct (E2C) in which two extracellularly accessible cysteines had been mutated (C90A/C306A). E2C displayed little sensitivity to MTSET and uptake properties identical to the hDAT WT (Table III) . As shown in Fig. 6 , [ 3 H]dopamine uptake was essentially indistinguishable from control cells after 10 min treatment with 0.5 mM MTSET of COS-7 cells transiently expressing E2C. Also at higher concentrations (up to 5 mM) we observed no significant inhibition of uptake (data not shown).
Similar results were obtained for E2C when the MTSET reaction was performed in the presence of either 100 M dopamine or 10 M cocaine (Fig. 6 ). Addition of 10 M Zn 2ϩ also did not result in appreciable changes in MTSET sensitivity, either in the absence or presence of dopamine or cocaine (Fig. 6 ). Taken together, these data suggest that E2C is an appropriate background for the I159C mutation.
The E2C I159C mutant exhibited uptake properties similar to the hDAT WT and the E2C background (Tables II and III) . The K m values for [ 3 H]dopamine uptake were essentially identical and the V max value for E2C I159C was not significantly different from that of WT (Tables II and III) . Surprisingly, MTSET treatment (0.5 mM) of E2C I159C did not result in a profound decrease in [ 3 H]dopamine uptake as previously reported for the corresponding mutation in NET (I155C) using a similar MTSET concentration (17) . As shown in Fig. 6 , only a small 10 -15% decrease in response to 0.5 mM MTSET was observed in E2C I159C as compared with the control mutant E2C, and this decrease was not statistically significant (p Ͼ 0.05, one-way analysis of variance followed by Newman-Keuls multiple comparison post-hoc). This is in clear contrast to the ϳ80% inactivation previously observed in NET I155C (17) . In addition, in the presence of 100 M dopamine or 10 M cocaine the small inhibition observed in E2C I159C in response to 0.5 mM MTSET did not change significantly (p Ͼ 0.05) ( Fig. 6 ). At higher concentrations of MTSET (5 mM) we did observe inhibition of uptake in E2C I159C (20 -30%), but cocaine and dopamine did not affect this inhibition (data not shown). The presence of Zn 2ϩ , either alone or together with dopamine or cocaine, did not alter the effect of MTSET on E2C I159C (Fig. 6) .
The apparent discrepancy between our observations in DAT and the previous observations in NET was not because of differences in the experimental set-up, such as, for example, the use of different cells (COS-7 cells versus HeLa cells), because we also mutated Ile-155 in NET to cysteine and observed the same MTSET sensitivity of this mutant as previously reported (data not shown). Thus, the data strongly suggest that Ile-159 (DAT)/Ile-155 (NET) is considerably more accessible in NET than in DAT, despite the high degree of homology between the two transporters (ϳ70% sequence identity).
Notwithstanding the small effect of MTSET on E2C I159C, we did insert K264A, Y335A, and D345A into both the E2C background and the E2C I159C background. All these constructs were functional, as assessed by measurement of [ 3 H]dopamine uptake (Table III and data not shown). E2C I159C/ K264A, E2C I159C/Y335A, and E2C I159C/D345A were analyzed in detail and showed uptake properties almost identical to those observed for the mutants in the WT background including strong potentiation by low micromolar concentrations of Zn 2ϩ (Tables II and III) . Treatment of the mutants lacking the cysteine in position 159 (E2C K264A, E2C Y335A, and E2C D345A) with MTSET (0.5 mM) had little effect on [ 3 H]dopamine uptake both in the absence and presence of dopamine or cocaine (Fig. 6) . Also in the presence of Zn 2ϩ , MT-SET treatment had only insignificant effects on [ 3 H]dopamine uptake in E2C K264A, E2C Y335A, and E2C D345A (Fig. 6 ). A different picture was observed, however, in E2C I159C/K264A, E2C I159C/Y335A, and E2C I159C/D345A. In the absence of Zn 2ϩ , MTSET still had little or no effect on [ 3 H]dopamine uptake, but addition of 10 M Zn 2ϩ caused a marked inhibition of uptake following treatment with 0.5 mM MTSET in all three mutants, with the largest effect found in E2C I159C/D345A (ϳ60% inhibition, p Ͻ 0.001, one-way analysis of variance with Newman-Keuls multiple comparison post-hoc test, Fig. 6A ) followed by E2C I159C/K264A (ϳ45% inhibition, p Ͻ 0.001, Fig.  6A ) and E2C I159C/Y335A (ϳ28% inhibition, p Ͻ 0.01, Fig. 6A ).
FIG. 3. The effect of Zn 2؉ on [ 3 H]dopamine uptake in hDAT WT and mutant transporters. Zn 2ϩ inhibition of [ 3 H]dopamine uptake in COS-7 cells transiently expressing hDAT WT (dark squares), or K264A
(open circles), D345A (dark triangles), and D436A (open diamonds) mutant transporters, respectively. A, a representative experiment (out of at least three) to illustrate the potentiating effect of Zn 2ϩ on mutant transporters. Note that the experiment was performed with a subsaturating concentration of [ 3 H]dopamine causing the uptake of the mutant transporters to be relatively higher with increasing Zn 2ϩ compared with WT because of the lower K m of the mutants (see Table I This provides evidence that Zn 2ϩ alters the conformational equilibrium of these mutants, thereby making the cysteine in position 159 more accessible to MTSET. Interestingly, dopamine protected against the inactivation observed in the presence of Zn 2ϩ in E2C I159C/D345A and E2C I159C/K264A (p Ͻ 0.001, Newman-Keuls multiple comparison post-hoc test, Fig.  6B ) similar to its effect in NET I155C (17) . However, in E2C I159C/Y335A we did not see significant protection by dopamine ( Fig. 6B) .
Cocaine (10 M) strongly potentiated the inactivation by 0.5 mM MTSET in all three mutants (Fig. 6 ). In the absence of Zn 2ϩ , cocaine increased the inactivation of E2C I159C/K264A and E2C I159C/D345A from ϳ10 and ϳ15%, respectively, to ϳ55 and ϳ68%, respectively (p Ͻ 0.001, Fig. 6C ). The addition of Zn 2ϩ did not further change this inactivation (Fig. 6C) . In E2C I159C/Y335A, cocaine caused ϳ28% inactivation as compared with no inhibition in the absence of cocaine (p Ͻ 0.001), however, in the presence of Zn 2ϩ , inactivation increased from showing surface biotinylation of COS-7 cells transiently expressing hDAT WT, K264A, D345A, or Y335A. Surface-biotinylated protein was purified using monomeric avidin beads and analyzed using SDS-PAGE followed by immunoblotting with the rat monoclonal antibody MAB 369 directed against the NH 2 terminus of the hDAT (Chemicon) as described under "Materials and Methods." B, immunoreactive bands were quantified by densitometry measures using Scion Image (Scion, Frederick, MD). Data are mean Ϯ S.E. of four independent experiments. Note that surface expression of Y335A compared with WT hDAT has previously been reported (20) . ϳ30 to ϳ70% (p Ͻ 0.001, Fig. 6 ). These data indicate that cocaine and Zn 2ϩ both induce in the mutant transporters a conformational change that substantially increases the reactivity of I159C to MTSET.
To exclude the possibility that MTSET inactivation of E2C I159C/K264A, E2C I159C/Y335A, and E2C I159C/D345A in the presence of Zn 2ϩ and/or cocaine is because of exposure of an endogenous cysteine as an indirect result of mutating Ile-159 to cysteine, we mutated Ile-159 also to alanine in the background of E2C and E2C D345A. The resulting mutants (E2C I159A and E2C I159A/D345A) displayed uptake properties similar to E2C I159C and E2C I159C/D345A (data not shown); furthermore, we did not observe any significant MTSET inactivation of E2C I159A (data not shown) or E2C I159A/D345A either in the presence of Zn 2ϩ or cocaine (Fig. 6) . DISCUSSION Recently, we demonstrated that mutation of the highly conserved Tyr-335 in the third ICL of hDAT dramatically alters the functional effect of high affinity Zn 2ϩ binding to the transporter (20) . Moreover, the mutation of Tyr-335 to alanine (Y335A) was accompanied by a substantial loss of affinity for cocaine-like inhibitors (ϳ150-fold) rendering the transporter essentially insensitive to modulation by these psychostimulants (20) . It has also recently been proposed that Y335A might act as a dominant negative mutation impairing the function of a co-expressed WT transporter (27) . In the current study, we sought to identify additional mutants that displayed a similar phenotype as Y335A by mutating 16 selected residues in the predicted intracellular domain of the hDAT. Moreover, we applied the substituted cysteine accessibility method (28) to establish a structural read-out reflecting the conformational state of mutant transporters characterized by a Y335A-like phenotype.
Three of the 16 mutants displayed characteristics similar to that of Y335A. Thus, in K264A, D345A, and D436A both the V max values and the K m for [ 3 H]dopamine uptake decreased considerably (Table I) . For D345A and D436A these properties are in agreement with earlier observations (29) . Similar to our previous finding in Y335A, in the presence of micromolar concentrations of Zn 2ϩ , the uptake capacity in all three mutants was potentiated ( Fig. 2 and Table II ). In D345A and K264A, which were characterized in detail, the V max values were restored to the V max observed for WT in the presence of Zn 2ϩ (Table II) . Although the relative potentiation of Y335A was higher than that found in K264K and D345A (Fig. 2) , Zn 2ϩ was not capable of restoring V max to WT level in this mutant (Table  II and Ref. 20) . In both K264A and D345A the apparent affinities for cocaine-like inhibitors (cocaine itself and CFT) and for GBR 12,909 were clearly decreased but by 1 order of magnitude and not 2 orders of magnitude as observed in Y335A (Table II) . Nonetheless, given that the qualitative changes in the three mutations are similar, i.e. characterized by potentiation rather than inhibition by Zn 2ϩ , decreased inhibitor affinity, and increased substrate affinity, we infer that the molecular mechanisms underlying the observed changes are similar.
We envisioned previously that the characteristic phenotype of Y335A was because of disruption of critical intramolecular interactions, which lead to a constitutive change in the distribution between conformational states in the transport cycle (20) . This interpretation of the Y335A data introduced a new paradigm in this class of transporters with parallels to the concept underlying constitutively activating mutations in G protein-coupled receptors (30 -32) . Substantial experimental evidence suggests that such mutations promote the release of intramolecular constraining interactions in the receptor molecule, leading to spontaneous formation of the active receptor state and, thus, a change in the conformational equilibrium between inactive and active receptor conformations (30 -32) . Importantly, constitutively activating mutations in G proteincoupled receptors have proven to be highly valuable tools for gaining insight into the molecular function of this family of membrane proteins (30 -32) as well as for drug development.
To substantiate our hypothesis and thus to assess the conformational state of the transporter we have characterized the accessibility of a cysteine engineered into position 159 in TM 3 of hDAT to the positively charged sulfhydryl-reactive compound MTSET. This position was chosen because Rudnick and co-workers (17) recently provided evidence that the accessibility of MTSET to a cysteine engineered in the corresponding position of the homologous SERT and NET is dependent on whether the transporter assumes an outward facing conformation versus an inward facing conformation. According to the classical alternating access model for the function of this class of transporters, it was hypothesized that this position is part of an extracellular gate and thus accessible in the outward facing conformation when the external gate is open, but buried in the protein structure in the inward facing conformation when the external gate is predicted to be closed (17) .
Taken together, the MTSET data from the three mutants (E2C I159C/K264A, E2C I159C/Y335A, and E2C I159C/D345A) are consistent with our predictions. In the absence of Zn 2ϩ , MTSET did not cause a measurable decrease in [ 3 H]dopamine uptake capacity in these mutants (Fig. 6 ). This is in accordance with the notion that in the absence of Zn 2ϩ the mutant transporters primarily reside in an inward facing conformation with position 159 buried in the protein structure. However, the presence of 10 M Zn 2ϩ enhanced inactivation by MTSET and thus accessibility of I159C to the external medium as reflected by ϳ60% inactivation in D345A, ϳ45% in K264A, and ϳ30% in Y335A (Fig. 6 ). This suggests that Zn 2ϩ is capable of restoring a conformational equilibrium in the three mutants with a larger fraction of transporter molecules stabilized in an out-ward facing conformation in which position 159 is exposed. Interestingly, in K264A and D345A we observed that dopamine is capable of protecting against this inactivation similar to what was observed previously in NET I155C (17) . This is consistent with the prediction that dopamine binding initiates transport, resulting in a higher fraction of transporters in an inward facing conformation in which I159C is inaccessible to MTSET.
Although the MTSET mutant data corresponded to our predictions, this was not the case for the WT. Despite the homology of DAT with NET and SERT, MTSET caused only a minor and statistically insignificant inhibition (ϳ10%) in hDAT E2C I159C under conditions in which MTSET inhibited uptake by 60 -80% in NET and SERT (17) . This was not altered either by the addition of dopamine or cocaine, in clear contrast to NET, in which dopamine protected robustly against MTSET inactivation and cocaine strongly enhanced inactivation by MTSET (17) . This suggests a conformational difference between DAT and NET/SERT as well as between DAT and the intracellular DAT mutants, with DAT predominantly assuming a conformation in which position 159 is buried, in contrast to NET, SERT, and the mutants in the presence of Zn 2ϩ . Given the profound effect on uptake of MTSET derivatization of I179C and I155C in the homologous SERT and NET, respectively, it seems unlikely that I159C in hDAT E2C reacts with MTSET but that this does not result in impairment of uptake. The finding that E2C I159C in the context of Y335A, D345A, and K264A can be profoundly inactivated by MTSET further argues against this possibility. Moreover, it could be argued that regardless of whether MTSET reacts or not with I159C in E2C I159C, the ability of Zn 2ϩ and cocaine to enhance MTSET inactivation selectively in E2C I159C/Y335A, E2C I159C/D345A, and E2C I159C/K264A and not in E2C I159C can only be explained by a conformational difference between these mutants and E2C I159C. Similarly, the different response to MTSET in hDAT E2C I159C as compared with the corresponding mutation in SERT and NET must be indicative of conformational differences between the different transporters.
The data shown in Fig. 6 suggest that Zn 2ϩ promoted activation of the mutant transporters does not completely restore the conformational equilibrium of the hDAT WT but likely generates a transporter with a conformational equilibrium similar, but not necessarily identical, to NET. A partial reversal by Zn 2ϩ is supported directly by the observation that the K m values for both [ 3 H]dopamine and [ 3 H]norepinephrine are lower in the mutants and more "NET-like" even in the presence of Zn 2ϩ (Table II ). In addition, the V max ratio between that of [ 3 H]dopamine and [ 3 H]norepinephrine tended to be more NETlike than "DAT-like" in the mutants also in the presence of Zn 2ϩ (Table IV) . The apparent affinities for inhibitors are also only partially "normalized" by Zn 2ϩ in the three mutants (Table II) . From a kinetic perspective one explanation for the data could be that when substrate is absent a larger fraction of the NET transporter molecules than of the DAT transporter molecules reside in the outward facing conformation with the putative external gate open and with position 155 (NET)/159 (DAT) exposed. The DAT might reside relatively briefly in this conformation no matter whether Zn 2ϩ is present or not. As a consequence the likelihood of MTSET reacting with I159C in the DAT would be substantially lower than in the NET. In the DAT mutants (K264A, Y335A, and D345A), the chances that the transporter assumes the outward facing conformation in the absence of Zn 2ϩ may be even further reduced. In the presence of Zn 2ϩ , however, the fraction might increase substantially, resulting in an equilibrium similar but not necessarily identical to that of the hNET. In other words, the Zn 2ϩ -bound mutant, like NET, resides longer in the outward facing conformation with the external gate open, in contrast to DAT WT, which is less likely to assume this conformational state. An alternative explanation would be the existence of structural intermediates between the outward and inward facing conformations. It could be envisioned, for example, that I159C selectively is accessible in such an intermediary conformation in which the DAT only briefly resides in contrast to NET and SERT, which may reside in such a conformation for longer. In case of the mutants, Zn 2ϩ might promote a conformational distribution in which such a structural intermediate is more populated than in the DAT WT, resulting in the NET-accessibility pattern.
Although cocaine has a profound effect on the accessibility of I159C in all three mutants, both in the absence and presence of Zn 2ϩ , cocaine does not promote accessibility of I159C in the E2C background. This suggests that the cocaine-bound state of DAT WT is distinct from that of the mutant transporters. Moreover, it suggests that the cocaine-bound state of NET is different from that of DAT and possibly more similar to that of the mutants, because MTSET dramatically enhanced accessibility of the corresponding I155C in this transporter (17) . Importantly, the profound effect of cocaine on MTSET accessibility in the mutants also lends further support to the growing realization that cocaine is not a "silent" inhibitor but rather promotes significant conformational changes in the monoamine transporters (15, 17, 33) . In this context, loss of affinity in K264A, Y335A, and D345A for cocaine and cocaine-like compounds as well as for structurally distinct inhibitors such as GBR 12,909 is highly interesting. The loss of affinity for inhibitors clearly demonstrates a key role of the mutated residues in maintaining the structural integrity of the inhibitor binding pocket. We think these results most likely are not indicative of a direct involvement of the mutant residues in inhibitor binding, but rather a consequence of an altered conformational equilibrium, in which the transporter more rarely assumes the high affinity binding state for cocaine and other inhibitors. Hence, binding of the inhibitors requires a substantial change in conformational distribution and thus more energy in comparison to binding to the WT, as directly reflected in the lower apparent affinities. This interpretation of our data further underlines the necessity of being extremely cautious when interpreting the growing body of mutagenesis data showing changes in apparent affinities for cocaine and other inhibitors (34 -37) . Thus, inferences about direct interactions must be supported by other approaches, such as photoaffinity labeling (38, 39) .
Summarized, we have identified additional residues, which upon mutation display phenotypic characteristics similar to what we have previously observed upon mutating Tyr-335 (20) . We propose that these characteristics are the result of disrupting critical intramolecular interactions leading to an altered conformational equilibrium. Interestingly, the three residues identified (Lys-264, Asp-345, and Asp-436) are either positively or negatively charged, suggesting that intramolecular salt bridges could be important. Notably, for certain G protein-coupled receptors it is known that intramolecular salt bridges play a key role in regulating the equilibrium between inactive and active receptor states (40, 41) . A similar scenario could occur in transporters such as DAT, i.e. the transport cycle might be controlled by continuous disruption and reformation of intramolecular salt bridges involving residues such as Lys-264, Asp-345, and Asp-436. We attempted to test specifically whether Lys-264 and Asp-345 or Lys-264 and Asp-436 formed a salt bridge by exploring the possibility of interchanging their positions (K264D/D345K and K264D/D436K) but unfortunately this resulted in non-functional transporters (data not shown). It is, furthermore, intriguing that the mutants with inverted Zn 2ϩ sensitivity all are situated in the three "central" short ICLs of the transporter, ICL 2, 3, and 4 ( Fig.  1) , especially because the accessibility of MTS reagents to cysteines in these loops in hDAT and in SERT have been shown to be sensitive to the presence of substrate and/or inhibitors (15, 16, 18, 19) . It is attractive to suggest that these loops form part of a conformationally active intracellular gating domain that controls access of the substrate to the intracellular milieu and in doing so plays a key role in regulating the overall conformational equilibrium of the transport cycle. Residues critical for maintaining this equilibrium of the transport cycle might, however, also be found in other parts of the transporter. Recent electrophysiological analysis of two mutations at the extracellular end of TM7 in the ␥-aminobutyric acid transporter-1 indicate the presence of major changes in distribution of conformational states in the translocation cycle and accordingly that residues on the extracellular face of the transporter also can be critical for regulating the conformational distribution (42) .
